Phase IB Study of FOLFIRINOX Plus PF-04136309 in Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma.
Phase of Trial: Phase I
Latest Information Update: 26 Sep 2016
At a glance
- Drugs PF 4136309 (Primary) ; Fluorouracil; Folinic acid; Irinotecan; Oxaliplatin
- Indications Pancreatic cancer
- Focus Adverse reactions
- 15 Sep 2016 Status changed from active, no longer recruiting to completed.
- 04 Apr 2016 Results published in the Lancet Oncology
- 22 Mar 2016 Planned End Date changed from 1 Mar 2016 to 1 Sep 2016 as reported by ClinicalTrials.gov.